Education
About Us
Working with TipRanks
Follow Us
ArriVent BioPharma, Inc. (AVBP)
NASDAQ:AVBP
RESEARCH TOOLSreports
Total Valuation
ArriVent BioPharma, Inc. has a market cap or net worth of $670.35M. The enterprise value is $679.26M.
Market Cap$670.35M
Enterprise Value$679.26M
Share Statistics
ArriVent BioPharma, Inc. has 34,045,193 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding34,045,193
Owned by Insiders1.53%
Owned by Institutions4.39%
Financial Efficiency
ArriVent BioPharma, Inc.’s return on equity (ROE) is -0.31 and return on invested capital (ROIC) is 0.00%.
Return on Equity (ROE)-0.31
Return on Assets (ROA)-0.29
Return on Invested Capital (ROIC)0.00%
Return on Capital Employed (ROCE)0.00
Revenue Per Employee0.00
Profits Per Employee-1.55M
Employee Count52
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of ArriVent BioPharma, Inc. is -10.42. ArriVent BioPharma, Inc.’s PEG ratio is -0.58.
PE Ratio-10.42
PS Ratio0.00
PB Ratio3.25
Price to Fair Value3.25
Price to FCF-11.94
Price to Operating Cash Flow-11.94
PEG Ratio-0.58
Income Statement
In the last 12 months, ArriVent BioPharma, Inc. had revenue of 0.00 and earned -80.49M in profits. Earnings per share was -2.56.
Revenue0.00
Gross Profit0.00
Operating Income0.00
Pretax Income-80.49M
Net Income-80.49M
EBITDA0.00
Earnings Per Share (EPS)-2.56
Cash Flow
In the last 12 months, operating cash flow was -70.21M and capital expenditures 0.00, giving a free cash flow of -70.21M billion.
Operating Cash Flow-70.21M
Free Cash Flow-70.21M
Free Cash Flow per Share-2.06
Dividends & Yields
ArriVent BioPharma, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.31
52-Week Price Change10.06%
50-Day Moving Average20.00
200-Day Moving Average24.96
Relative Strength Index (RSI)48.14
Average Volume (3m)225.18K
Important Dates
ArriVent BioPharma, Inc. upcoming earnings date is Aug 13, 2025, TBA Not Confirmed.
Last Earnings DateMay 7, 2025
Next Earnings DateAug 13, 2025
Ex-Dividend Date―
Financial Position
ArriVent BioPharma, Inc. as a current ratio of 13.14, with Debt / Equity ratio of 0.07%
Current Ratio13.14
Quick Ratio13.14
Debt to Market Cap0.00
Net Debt to EBITDA0.00
Interest Coverage Ratio0.00
Taxes
In the past 12 months, ArriVent BioPharma, Inc. has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
ArriVent BioPharma, Inc. EV to EBITDA ratio is 0.00, with an EV/FCF ratio of -10.88.
EV to Sales0.00
EV to EBITDA0.00
EV to Free Cash Flow-10.88
EV to Operating Cash Flow-10.88
Balance Sheet
ArriVent BioPharma, Inc. has $218.86M in cash and marketable securities with $0.00 in debt, giving a net cash position of -$218.69M billion.
Cash & Marketable Securities$218.86M
Total Debt$0.00
Net Cash-$218.69M
Net Cash Per Share-$6.42
Tangible Book Value Per Share$8.19
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for ArriVent BioPharma, Inc. is $39.75, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$39.75
Price Target Upside101.88% Upside
Analyst ConsensusStrong Buy
Analyst Count4
Revenue Growth Forecast―
EPS Growth Forecast-15.71%